

VOLUMEN XLV

NUMERUS Suppl. 1

LIBRI ONCOLOGICI

CROATIAN JOURNAL OF ONCOLOGY

Zagreb, 2017

CROATIAN JOURNAL OF ONCOLOGY
LIBRI ONCOLOGICI

Publisher

Sestre milosrdnice University Hospital Center
University Hospital for Tumors, Zagreb, Croatia

Editor-in-Chief

Danko Velimir Vrdoljak

Editors

Lidija Beketić-Orešković, Zvonko Kusić, Božena Šarčević

Associate Editors

Iva Kirac – Experimental Research
Mladen Stanec – Surgical Oncology
Robert Šeparović – Medical Oncology
Hrvoje Šobat – Radiation Oncology

Technical Editor

Anica Vrdoljak

Editorial Board

Gordana Brozović, Krešimir Gršić, Željko Herceg, Nada Kraljević, Ljiljana Mayer, Ivan Milas, Aleksandar Milenović, Marija Milković Periša, Marija Pastorčić-Grgić, Vesna Pavlica, Mario Puljiz, Vesna Ramljak, Andrej Roth, Sanda Šitić, Ljiljana Štefančić, Tiha Vučemilo, Darko Županc

Editorial Council

D. Babić (Zagreb), M. Banović (Zagreb), A. Bolanča (Zagreb), D. Chudy (Zagreb), E. Čepulić (Zagreb), T. Čufer (Ljubljana), N. Đaković (Zagreb), D. Eljuga (Zagreb), J. Fajdić (Požega), G. Fisher (Stanford), M. Gamulin (Zagreb), D. Grdina (Chicago), M. Grgić (Zagreb), D. Gugić (Osijek), H. Haler (Rijeka), B. Jakšić (Zagreb), J. Jassem (Gdansk), Ž. Jelinčić (Zagreb), A. Juretić (Zagreb), D. Kalafatić (Zagreb), S. Kaštelan (Zagreb), Ž. Kaštelan (Zagreb), J. Konja (Zagreb), Z. Krajina (Zagreb), S. Kurbel (Osijek), B. Labar (Zagreb), N. Lakayo (Stanford), S. Levanat (Zagreb), D. Marčinko (Zagreb), L. Milas (Houston), D. Miličić (Zagreb), B. Nagy (Zagreb), S. Orešković (Zagreb), P. Ozretić (Zagreb), K. Pavelić (Rijeka), S.Ž. Pavletić (Bethesda), R. Pirker (Wien), M. Radačić (Zagreb), N. Rudan, (Zagreb), M. Solarić (Zagreb), M. Šamija (Zagreb), F. Šantek (Zagreb), B.I. Šikić (Stanford), E. Vrdoljak (Split), Ž. Vujašković (Baltimore), M. Zovak (Zagreb), N. Žarković (Zagreb)

Indexed in EMBASE/Excerpta Medica

Editorial Office:

LIBRI ONCOLOGICI, Ilica 197, 10 000 Zagreb, Croatia, P.O. Box 427,

Phone (385 1) 37 83 522, Fax (385 1) 37 75 536

Web site: <http://hrcak.srce.hr/libri-oncologici>

e-mail: libri.oncologici@kbcsm.hr

The journal is published three times a year. Orders can be placed directly to the Editorial Office.

Price per copy 60 HRK. Annual subscription rates in Croatia: 300 HRK + VAT for institutions, 150 HRK + VAT for individuals and 60 HRK + VAT for students, to be remitted with Hrvatska poštanska banka, account HR31 2390 0011 1004 1610 4 Ref.No.3 (for LIBRI ONCOLOGICI).

Annual subscription abroad - equivalent of US\$ 50 to be paid into the foreign currency account with Hrvatska poštanska banka, IBAN: HR31 2390 0011 1004 1610 4 (Ref.No.3), BIC code: HPBZHR2X (for LIBRI ONCOLOGICI)

Cover Design: Osman Berberović

Typesetting and printed by DENONA d.o.o., Zagreb



1. regionalni kongres internističke onkologije 1. regionalni kongres onkološke farmacije

**Hrvatsko društvo za internističku onkologiju Hrvatskog liječničkog zbora
Sekcija za onkološku farmaciju Hrvatskog farmaceutskog društva**

4. – 7. svibanj 2017., hotel Valamar Lacroma Dubrovnik, Dubrovnik, Hrvatska

1st Regional Congress of Medical Oncology 1st Regional Congress of Oncology Pharmacy

**Croatian Society for Medical Oncology, Croatian Medical Association
Oncology Pharmacy Session, Croatian Pharmaceutical Society**

4th – 7th May 2017, hotel Valamar Lacroma Dubrovnik, Dubrovnik, Croatia

Supplement editors:

Damir Vrbanec

Ana Tečić Vuger

Zagreb, Croatia
May, 2017

ORGANIZER

Hrvatsko društvo za internističku onkologiju Hrvatskog liječničkog zbora
Hrvatski liječnički zbor
Sekcija za onkološku farmaciju Hrvatskog farmaceutskog društva
Hrvatsko farmaceutsko društvo
European Society for Oncology Pharmacy – ESOP

Chair of the Organizing Committee

Damir Vrbanec

Organizing Committee

Damir Vrbanec
Robert Šeparović
Borislav Belev
Natalija Dedić Plavetić
Anes Pašić
Ana Tečić Vuger
Vesna Pavlica
Marko Skelin
Davorin Herceg
Marko Jakopović

Scientific Committee

Semir Bešlija
Davorin Radosavljević
Timur Cerić
Sven Kurbel
Siniša Radulović
Janja Ocvirk
Renata Dobrila Dintinjana
Stjepko Pleština
Darko Takač
Vladimir Todorović
Martina Kranjec Šakić

Sponsors & Donators

Servier
Amgen
Pliva
Astellas
Providens
Pfizer
Alvogen
AstraZeneca
Bristol-Meyers Squibb
Fresenius Kabi
Janssen
Merck
MSD
Novartis
PharmaSwiss
Roche
Sanofi Genzyme
Yasenka

CONTENTS

ORAL PRESENTATIONS

Borislav Belev		
S1 - Immunotherapy in bladder cancer	3
Simona Borštnar		
S2 - Therapeutic options in treatment of hormonal resistant breast cancer	4
Natalija Dedić Plavetić		
S3 - Future treatment of triple-negative breast cancer	5
Zlatko Dembić		
S4 – Genomics and epigenomics in cancer research and their potential use in diagnostics, prognostics and therapy	6
Milena Gnjiđić		
S5 - Aggressive variant of castration resistant prostate cancer: Case report	7
Milena Gnjiđić		
S6 - Primary mediastinal germ cell tumors: Case reports	8
Davorin Herceg		
S7 - Biological therapy of malignant melanoma	9
Marko Jakopović, Miroslav Samaržija		
S8 - What is optimal treatment for majority of NSCLC patients: Treatment of patients with NSCLC without activating mutations	10
Lidija Kandolf Sekulovic		
S9 - Access to innovative medicines for metastatic melanoma in South-East Europe	..	11
Janja Ocvirk		
S10 - Immunotherapy of metastatic melanoma	12
Janja Ocvirk		
S11 - Hepatocellular carcinoma	13
Anes Pašić, Timur Cerić, Semir Bešlija		
S12 - Role of angiogenesis inhibitors in treatment of ovarian carcinoma	14

Sanja Pleština	
S13 - Metastatic non-small cell lung cancer treatment algorithm in Croatia	15
Lazar Popovic	
S14 - Breast cancer immunotherapy	16
Davorin Radosavljević, Jelena Spasić	
S15 - From personalized to precise medicine – current status of molecularly targeted therapy in advanced non-small cell lung cancer (NSCLC)	17
H. Joachim Seitz	
S16 - Survival strategies of cancer cells	18
Tajana Silovski	
S17 - PARP inhibitors in ovarian cancer treatment	19
Marko Skelin	
S18 - Liposomal irinotecan in the treatment of pancreatic cancer	20
Jelena Spasic, Davorin Radosavljevic	
S19 - Treatment algorithm of non-small cell lung cancer (NSCLC) in 2017 in Serbia	21
Ljiljana Stamatovic	
S20 - HER2-positive breast cancer: Challenges and progress in the treatment	22
Robert Šeparović, Ana Tečić Vuger	
S21 - What is new in the treatment of recurrent, persistent or metastatic cervical cancer	24
Robert Šeparović	
S22 - Nutrition of oncology patients – new guidelines of the European Society for Clinical Nutrition and Metabolism (ESPEN)	25
Breda Škrbinc	
S23 - Options and sequencing of systemic treatment of metastatic renal cell carcinoma(mRCC) – clinical practise and clinical guidelines	26
Miomir Šoškić	
S24 - Anticoagulant therapy in patients with cancer	27
Ana Tečić Vuger, Robert Šeparović	
S25 - Tumor infiltrating lymphocytes (TIL) and androgene receptors (AR) in triple – negative breast cancer (TNBC) – new biomarkers on horizon?	28
Zorica Tomašević	
S26 - Recurrent ovarian cancer (ROC): treatment recommendations and every day clinical practice	29
Olivera Spasovska, Biljana Grozdanovska	
S27 - Cooperation and experience of clinical pharmacist and oncologist through the case of a patient with colon cancer	30

Damir Vrbanec, Robert Šeparović, Vesna Pavlica, Marko Skelin S28 – Workshop: Biological therapy – from production and administration to side effects monitoring	31
Goran Arbanas, Jurica Vrbanec, Robert Šeparović, Olivera Spasovska S29 – Workshop: Love and sexuality in oncology patients	32
Dahna Arbanas S30 - Counseling center for palliative care	33
Irena Netikova S31 - Immunotherapy in oncology - interdisciplinary cooperation among immunologist, oncologist and pharmacist	34
Vesna Pavlica S32 - Novelties in antiemetic supportive therapy	35
Martina Kranjec Šakić S33 - Value-based medicine and pharmacy	36
Martina Kranjec Šakić, Eugen Javor S34 - Evaluation of pharmacist counseling on oncology patients	37
Danijela Ledić Drvar, Davorin Herceg, Irena Netikova Štenglova S35 – Workshop: Melanoma – new systemic therapy and its side-effects	38
Marko Skelin S36 - Left-right colon cancer and the effectiveness of targeted antibodies	39
Lidija Gajski, Olivera Spasovska, D.Aleksić, Vesna Pavlica S37 - Central preparation of antineoplastic drugs: practice and experiences	40
Vesna Pavlica S38 - Oncology pharmacy and oncology pharmacy education	41

POSTERS

Denis Baricevic, Marko Jakopovic, Marinka Baricevic P1 - Acquired rhinophyma as a paraneoplastic manifestation of non-small cell lung cancer	45
Ivan Bilić, Nada Božina, Lana Ganoci, Marko Kralik, Stjepko Pleština, Damir Vrbanec P2 - UGT1A1*28 polymorphism and toxicity of FOLFIRI protocol – a single-institution cohort	46
Biljana Blažeković, Marija Kindl, Maja Bival Štefan, Mateja Mervić, Sanda Vladimir-Knežević P3 - Preclinical evidence on the anticancer properties of phytocannabinoids	47
Mislav Čonkaš, Sara Šošić, Luka Kužat, Zvonimir Magaš, Marijan Žvorc, Slavko Gašparov P4 - Colon carcinoma with a metastasis into breast, a case study	48

Jelena Dimitrijevic, Snezana Bosnjak, Fedja Djordjevic, Natasa Bakic, Natasa Lazin, Iva Kezic	
P5 - The use of Edmonton Symptom Assessment System (ESAS) in patients with metastatic melanoma at the time of admission to Medical Oncology Clinic (MOC), Institute for Oncology and Radiology of Serbia (IORS)	49
Ivana Durutović, Vladimir Todorović	
P6 - Influence of molecular subtypes of metastatic breast cancer on clinical manifestations and disease outcome	50
Fedja Đorđević, Nemanja Stanić, Jelena Dimitrijević, Jelena Spasić, Ana Žilić, Snežana Bošnjak, Davorin Radosavljević, Snežana Šušnjar	
P7 - The efficacy and tolerability of slow-release (SR) hydromorphone in the treatment of cancer dyspnea in lung cancer patients: experience from the Institute for oncology and radiology of Serbia (IORS)	51
Milena Gnjidić, Dino Dujmović	
P8 - Metastatic renal cell carcinoma: First-line treatment choice in everyday practice – personal experience	52
Robert Grubišić-Čabo, Ivan Krečak, Matilda Kinkela, Filip Grubišić-Čabo	
P9 - When to stop the treatment of venous thromboembolism in cancer patients	53
Petra Jurčić, Ivan Budimir, Marko Nikolić, Dominik Kralj	
P10 - Malignancy-related ascites; clinical significance and impact on prognosis	54
Petra Jurčić	
P11 - Efficacy and safety of antivasular drug after anti-EGFR; aflibercept after panitumumab, a clinical case	55
Kristina Juskić, Ljiljana Stamatović, Marijana Milović-Kovacević	
P12 - Long-term chemiosensitivity of epithelial ovarian cancer: case report	56
Kristina Katić, Višnja Matković, Ante Ćorušić	
P13 - Response to treatment with topotecan in patient with recurrent ovarian cancer considering sensitivity to the platinum	57
Ana Koši Kunac, Zrna Antunac Golubić, Milena Gnjidić, Iva Zubatović Đunđenać, Željko Kaštelan, Marija Gamulin	
P14 - Epidemiologic analysis of patients with testicular cancer during a 5-year period in the Referral center for treatment of germ cell tumors and extragonadal germ cell tumors in Republic of Croatia	58
Anamarija Kovač Peić, Matea Kršan, Zvezdana Borić Mikez, Ivana Vučinić Ljubičić, Hrvoje Holik, Božena Coha	
P15 - Lung cancer – experience of a small center	59
Lucija Kovačević, Natalija Dedić Plavetić, Damir Vrbanec	
P16 - What is the future of hormone receptor positive HER2 negative metastatic breast cancer treatment?	60
Tatjana Ladenhauser	
P17 - Imatinib as second-line treatment for inoperable progressive mesenterial desmoid tumor and familial adenomatous polyposis – a case report	61

Iva Marinčić, Petra Vuković, Jelena Raguž, Nikolina Vincelj, Robert Šeparović P18 - Single institution experience in fertility preservaion in female patients diagnosed with early stage cancer	62
Marija Miletić, Mirjana Pavlović, Ana Tečić Vuger, Nikolina Vincelj, Iva Marinčić, Petra Vuković, Jelena Raguž, Robert Šeparović P19 - Our experience with palbociclib	63
Marija Milosavljevic, Nada Babovic P20 - Unusual pathohistological finding in patient with prostate cancer	64
Lidija Pavlović, Marijana Milović –Kovačević, Anđela Karaferić, Suzana Vasović, Ljiljana Stamatović P21 - Clinical outcome in patients with primary advanced or metastatic endometrial carcinoma treated with standard chemotherapy regimen according different histopathologic characteristics	65
Marijana Milovic-Kovacevic, Lidija Pavlovic, Andjela Karaferic, Suzana Vasovic, Ljiljana Stamatovic P22 - Tolerability of bevacizumab in triple-negative (TNBC) metastatic breast cancer patients: a single institution experience	66
Sonja Badovinac, Davorka Muršić, Marta Koršić, Kamelija Žarković, Marko Jakopović, Branka Čučević, Mihovil Roglić, Filip Popović, Miroslav Samaržija P23 - Nivolumab induced synchronous occurrence of polymyositis and hypothyroidism in a patient with squamous cell lung cancer	67
Ljubica Radmilović Varga, Kristina Krpina, Nikolina Vincelj, Natalija Dedić Plavetić, Ana Kulić, Jasminka Jakić Razumović, Damir Vrbanec P24 - Survival data on early, invasive breast cancer patients treated with adjuvant chemotherapy: ten years follow-up in University Hospital Center Zagreb	68
Jelena Raguž, Petra Vuković, Iva Marinčić, Nikolina Vincelj, Chiara Krstić, Monika Žepić, Ana Šahbazović, Robert Šeparović P25 - Trichiasis as a result of docetaxel chemotherapy for metastatic prosate cancer	70
Jelena Raguž, Petra Vuković, Iva Marinčić, Nikolina Vincelj, Sara Bilić Knežević, Iva Badžek, Robert Šeparović P26 - Neutrophil/lymphocyte ratio as a predictive value for treatment outcome after neoadjuvant therapy in locally advanced breast cancer patients	71
Luka Simetić, Krešimir Blažičević, Davorin Herceg P27 - The treatment of locally advanced or metastatic soft tissue sarcomas in the era of innovative therapies and hystorical review of therapies in Croatia Single center experience – University Hospital Centre Zagreb	72
Drazena Srdic, Ana Sverko-Peternac, Nora Nikolac, Ana Bacelic Gabelica, Marko Jakopovic, Sanja Plestina P28 - Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer - chemotherapy toxicity and prognostic value	73

Nemanja Stanic, Simonida Pupovac, Olivera Djokic, Dusica Gavrilovic, Snezana Susnjar P29 - The characteristics and long-term follow up of elderly breast cancer patients treated at Institute of oncology and radiology of Serbia	74
Miomir Šoškić, Vera Dabanović P30 - The interactions between herbal preparations and conventional drugs in oncology	75
Ana Tečić Vuger, Mirjana Pavlović, Tajana Silovski, Robert Šeparović, Žarko Bajić P31 - Correlates of depressive symptoms in breast cancer patients; a cross-sectional study in Croatia	76
Nikolina Vincelj, Ljubica Vazdar, Jelena Raguž, Iva Marinčić, Petra Vuković, Ana Tečić Vuger, Robert Šeparović P32 - Profile of patients with early HER2 positive breast cancer who developed cardiotoxicity during adjuvant trastuzumab in the University Hospital for Tumors	77
Sanda Vladimir-Knežević, Robert Šeparović, Vesna Pavlica, Ana Tečić Vuger, Mirjana Pavlović, Maja Bival Štefan P33 - Medical cannabis in symptomatic therapy of oncology patients	78
Petra Vuković, Jelena Raguž, Iva Marinčić, Nikolina Vincelj, Sara Bilić Knežević, Iva Badžek, Robert Šeparović P34 - Safety of generic capecitabine Kapetral as maintenance therapy in metastatic colorectal cancer	79
Petra Vuković, Jelena Raguž, Iva Marinčić, Nikolina Vincelj, Sara Bilić Knežević, Iva Badžek, Robert Šeparović P35 - Impact of increased body mass index on neoadjuvant treatment outcome in breast cancer patients	80
Ana Zilić, Snezana Bosnjak, Feđa Đorđević, Jelena Dimitrijevic, Marija Milosavljevic, Snezana Susnjar, Natasa Bakic P36 - Opiophobia in cancer patients	81
AUTHOR INDEX	83